Guillermo Villacampa

18PUBLICATIONS
272CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jan 22, 2026
Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Benedetta Conte, Fara Brasó-Maristany, Tomás Pascual

|Dec 03, 2025
Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial.

Eva Ciruelos, Tomás Pascual, Guillermo Villacampa

|Dec 01, 2025
Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial.

Mafalda Oliveira, Eva Ciruelos, Guillermo Villacampa

|Sep 19, 2025
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc.

Munetaka Takekuma, Shin Nishio, Satoshi Yamaguchi

|May 19, 2025
A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer - The MONEO Study.

Maria Alsina, Guillermo Villacampa, Carlos de Andrea

|Jan 09, 2025
RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial.

Guillermo Villacampa, Alba Llop-Guevara, Natalie Filmann

Pageof 3

Frequent Collaborators

4 joint publications

Josep Tabernero

4 joint publications

Ana Vivancos

4 joint publications

Tomás Pascual

4 joint publications

Aleix Prat